Long-term follow-up of colitis from checkpoint inhibitors
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have received at least one dose of an immune checkpoint inhibitor cancer drug (like Keytruda, Opdivo, or Yervoy).
- After starting that drug, you had a colonoscopy that showed inflammation in your colon (colitis).
- You did not have colitis, Crohn's disease, or ulcerative colitis before starting the checkpoint inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how bacteria in your gut, your immune system, and colon cancer interact. It aims to understand these connections to improve future treatments.
This study looks at long-term side effects in people who received immunotherapy for advanced melanoma and have had their cancer controlled for at least 3 years. Researchers want to understand how these treatments affect patients years later.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This study looks at how gut bacteria and immune activity differ in normal, pre-cancer, and cancer colon tissue. It may help researchers understand what changes in the body are linked to colon growth and how they could be targeted in the future.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
Hear when a new Immune Checkpoint Inhibitors-induced Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.